September 15, 2025 — Leads & Copy — Helmholtz Munich and Parse Biosciences have announced a strategic partnership to create a comprehensive atlas of lung disease perturbations. The study will use Parse Biosciences’ GigaLab platform to analyze human lung tissue and identify novel targets and cell circuits in lung health and disease. Researchers will characterize disease-specific responses of cells to 900 pharmacological interventions, utilizing ex-vivo tissue from normal control donor lungs and explant lung tissues from patients with chronic lung disease.
Prof. Herbert Schiller, Director of Helmholtz Munich’s Precision Regenerative Medicine Research Unit, will lead the initiative, aiming to improve lung tissue regeneration through targeted combination therapies. Prof. Fabian Theis, head of Helmholtz Munich’s Computational Health Center, emphasized the need for high-quality perturbation data to build foundational AI models of cell and tissue biology.
The Parse GigaLab, equipped with Parse’s Evercode chemistry, will rapidly produce large single-cell RNA sequencing datasets. Charlie Roco, PhD, Co-founder and Chief Technology Officer at Parse Biosciences, stated that this collaboration demonstrates how single-cell genomics can accelerate the development of better therapies.
Parse Biosciences, based in Seattle, is dedicated to advancing human health and scientific research through single-cell sequencing technology. Helmholtz Munich focuses on developing solutions for better health in a changing world, particularly in environmentally triggered diseases like diabetes and chronic lung diseases.
Contact:
Parse Biosciences
https://www.parsebiosciences.com/contact
Source: Parse Biosciences
Source: Parse Biosciences
